Convergence Investment Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Convergence Investment Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,117	Closed	-$167K	–	342
2019 Q3	$167K	Sell	6,117 -3,624	-37%	-$93.7K	0.05%	229
2019 Q2	$234K	Sell	9,741 -14,499	-60%	-$368K	0.06%	224
2019 Q1	$641K	Buy	+24,240	New	+$574K	0.14%	185
2018 Q4	–	Sell	-26,899	Closed	-$527K	–	403
2018 Q3	$527K	Buy	+26,899	New	+$511K	0.11%	212

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Convergence Investment Partners's HZNP Position: Q4 2019 in Review

Convergence Investment Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2019, closing a stake of 6,117 shares — an estimated $167K sold.

Convergence Investment Partners first reported a position in HZNP in Q3 2018 and held it in 4 quarters. The position peaked at $641K in Q1 2019. 281 funds tracked by Wall St. Rank hold HZNP as of Q4 2019.

Convergence Investment Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2019 after selling out during the quarter.
Convergence Investment Partners sold 6,117 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2019, an estimated $167K.
Convergence Investment Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 4 quarters.
Convergence Investment Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $641K in Q1 2019.
281 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2019.

Based on Convergence Investment Partners's 13F filing for Q4 2019, filed 22 Jan 2020.